Evidence map›Paper›PMID 29416195›Full record

ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2017

Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model.

Yasutaka Murai, Takeshi Ohta, Hironobu Tadaki, Katsuhiro Miyajima, Masami Shinohara, Fatchiyah Fatchiyah, Takahisa Yamada

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Evaluation of Preclinical and Clinical Studies Published in Medical Journals of Bosnia and Herzegovina: Methodology Issues.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2020
    Article
  5. Future Perspective of Diabetic Animal Models.Endocrine, metabolic & immune disorders drug targets · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yasutaka MuraiLaboratory of Animal Genetics, Division of Life and Food Sciences, Graduate School of Science and Technology, Niigata University, Niigata, Japan.
Takeshi OhtaLaboratory of Animal Genetics, Division of Life and Food Sciences, Graduate School of Science and Technology, Niigata University, Niigata, Japan.
Hironobu TadakiLaboratory of Animal Genetics, Division of Life and Food Sciences, Graduate School of Science and Technology, Niigata University, Niigata, Japan.
Katsuhiro MiyajimaDepartment of Nutritional Science and Food Safety Faculty of Applied Biosciences, Tokyo University of Agriculture, Tokyo, Japan.
Masami ShinoharaCLEA Japan Inc., Planning and Development Section, Tokyo, Japan.
Fatchiyah FatchiyahResearch Center of Smart Molecule of Natural Genetics Resources (SMONAGENES), Brawijaya University, Jl. Mayjend. Panjaitan. Malang, East Java, Indonesia.
Takahisa YamadaLaboratory of Animal Genetics, Division of Life and Food Sciences, Graduate School of Science and Technology, Niigata University, Niigata, Japan.
Niigata University · JPTokyo University of Agriculture · JPUniversity of Brawijaya · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe number of diabetic patients has recently been increasing worldwide, and numerous anti-diabetic drugs have been developed to induce good glycemic control. In particular, metformin, which exhibits glucose-lowering effects by suppressing gluconeogenesis in the liver, is widely used as a first line oral anti-diabetic drug for type 2 diabetes mellitus. MATERIAL AND

methodsIn this study, the pharmacological effects of metformin were investigated using female and male Spontaneously Diabetic Torii (SDT) fatty rats, a new obese type 2 diabetic model.

resultsTwo experiments were performed: an assessment of repeated treatment with metformin in female SDT fatty rats 5 to 13 weeks of age (experiment 1), and an assessment of repeated treatment with metformin in male SDT fatty rats 6 to 10 weeks of age (experiment 2). In female SDT fatty rats, metformin treatment led to good glycemic control, increases in sensory nerve conduction velocity, and improvements in pancreatic abnormalities such as irregular boundaries and vacuole form of islets. In male SDT fatty rats, metformin decreased blood glucose levels 4 weeks after treatment.

conclusionMetformin treatment led to maintained good glycemic control and improved neuropathy and pancreatic lesions in female SDT fatty rats. The SDT fatty rat is useful for the development of novel anti-diabetic agents that show potential to improve glucose metabolic disorders in the liver.

Indexed as

Disease Models, AnimalAnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2FemaleHypoglycemic AgentsMaleMetforminNeural ConductionObesityPancreasRatsBlood GlucoseHypoglycemic AgentsMetforminAnti-diabetic drugsMetforminSDT fatty ratType 2 diabetes

Identifiers

PMID29416195
PMCPMC5764610
OpenAlexW2775607619

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.